ACP
AVBP icon

Altitude Crest Partners’s ArriVent BioPharma AVBP Stock Holding History

Altitude Crest Partners’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-555,555
Closed -$9.92M – 29
2024
Q1 		$9.92M Buy
+555,555
New +$11.2M 4.25% 7

Other funds holding AVBP

HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
GCGM
General Catalyst Group Management Cambridge, Massachusetts $184M AUM 50.45% 1-Year Est. Return
HH
HSG Holding Na, Hong Kong $1.62B AUM 5.91% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Altitude Crest Partners's AVBP Position: Q2 2024 in Review

Altitude Crest Partners sold out of ArriVent BioPharma (AVBP) in Q2 2024, closing a stake of 555,555 shares — an estimated $9.92M sold.

Altitude Crest Partners first reported a position in AVBP in Q1 2024 and held it in 1 quarter. The position peaked at $9.92M in Q1 2024. 54 funds tracked by Wall St. Rank hold AVBP as of Q2 2024.

  • Altitude Crest Partners reported no remaining ArriVent BioPharma position as of Q2 2024 after selling out during the quarter.
  • Altitude Crest Partners sold 555,555 ArriVent BioPharma shares in Q2 2024, an estimated $9.92M.
  • Altitude Crest Partners first reported a position in ArriVent BioPharma in Q1 2024 and held it in 1 quarter.
  • Altitude Crest Partners's ArriVent BioPharma position peaked at $9.92M in Q1 2024.
  • 54 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q2 2024.

Based on Altitude Crest Partners's 13F filing for Q2 2024.